Bupropion Co-Administration for Dextromethorphan Metabolism Control

Solution Overview

Problem

Dextromethorphan is rapidly metabolized in the liver, leading to low plasma levels in extensive metabolizers, limiting its clinical utility, and existing treatments do not effectively address adverse events or metabolic issues.

Innovation Solution

Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism, increase plasma levels, and reduce adverse events, using a combination that includes a sustained release delivery system.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If dextromethorphan is administered to extensive metabolizers, then therapeutic effect is achieved, but plasma levels are low due to rapid metabolism

Engineering Contradiction:
Core Design Contradiction:
Quantity of substanceVSSpeed

Solution Approach 1:

Bupropion is introduced as an intermediary substance that inhibits the metabolic breakdown of dextromethorphan. By co-administering bupropion with dextromethorphan, the plasma levels of dextromethorphan are increased without directly altering the metabolism itself, thus resolving the contradiction between achieving therapeutic effect and maintaining adequate plasma levels in extensive metabolizers

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the pharmacokinetic parameter of dextromethorphan metabolism by introducing an inhibitory agent (bupropion). This parameter change slows down the metabolic rate, thereby increasing plasma levels and extending the duration of action, which directly addresses the issue of rapid metabolism in extensive metabolizers

Inventive Principle:
Principle #35Parameter changes

2Quantity of substance

If dextromethorphan is administered frequently to maintain plasma levels, then therapeutic efficacy is maintained, but dosing frequency increases and convenience decreases

Engineering Contradiction:
Core Design Contradiction:
Quantity of substanceVSEase of operation

Solution Approach 1:

Bupropion serves as a mediator that extends the duration of action of dextromethorphan by inhibiting its metabolism. This allows for reduced dosing frequency while maintaining therapeutic plasma levels, thereby improving ease of operation without compromising therapeutic efficacy

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

By using bupropion to inhibit metabolism, the invention achieves a partial extension of dextromethorphan's half-life. This partial action is sufficient to reduce dosing frequency from multiple times daily to once or twice daily, making the regimen more convenient while maintaining adequate plasma levels

Inventive Principle:
Principle #16Partial or excessive action

3Quantity of substance

If dextromethorphan is administered at high doses to increase plasma levels, then therapeutic effect is improved, but adverse events increase

Engineering Contradiction:
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

Bupropion acts as an intermediary that increases dextromethorphan plasma levels through metabolic inhibition rather than dose increase. This approach achieves therapeutic plasma levels without the associated adverse events that would result from administering higher doses of dextromethorphan alone

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

Instead of increasing the dose (mechanical approach), the invention uses a biochemical mechanism (metabolic inhibition by bupropion) to achieve the same therapeutic effect. This substitution allows for achieving therapeutic plasma levels without the harmful effects associated with high-dose administration

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enhances dextromethorphan plasma levels, reduces metabolic breakdown, and decreases adverse events, allowing for less frequent dosing without loss of efficacy, thereby improving therapeutic efficacy and safety.

Implementation Method 1

Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to inhibit metabolism, increase plasma levels

Methodology Applied
Scientific EffectMetabolic inhibition: Enzyme

Data Source

PatentUS20250205223A1Bupropion as a modulator of drug activity
Publication Date: 2025.06.26
  • US20250205223A1 patent drawing
  • US20250205223A1 patent drawing
  • US20250205223A1 patent drawing

AI summary

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.